Adverse Effects and Management of Selective Alpha‑1 Blockers

Cardiovascular Effects

Selective alpha‑1 blockers are associated with ejaculatory dysfunction, orthostatic hypotension, dizziness, nasal congestion, and asthenia; the side‑effect profile differs markedly among agents, with tamsulosin and silodosin causing more ejaculatory problems but fewer hypotensive events, whereas doxazosin and terazosin produce more cardiovascular adverse effects. 1
Postural (orthostatic) hypotension is the most clinically significant cardiovascular adverse effect, occurring most frequently with doxazosin and terazosin and least frequently with tamsulosin. 2
Tamsulosin shows the lowest probability of orthostatic hypotension among all alpha‑1 blockers, making it the safest option for older adults who are vulnerable to blood‑pressure‑related adverse events. 2

Ejaculatory dysfunction is significantly more common with tamsulosin and silodosin than with other alpha‑1 blockers. 1
Tamsulosin has a higher likelihood of causing ejaculatory dysfunction compared with other agents, although it is associated with fewer cardiovascular side effects. 2

All alpha‑1 blockers are linked to intra‑operative floppy iris syndrome (IFIS) during cataract surgery, characterized by a flaccid iris, progressive intra‑operative miosis, and possible iris prolapse. 1
Patients who are scheduled for cataract or glaucoma surgery should inform their ophthalmologist about any current or prior use of alpha‑1 blockers. 2
Initiation of an alpha‑1 blocker is not recommended in patients who have a planned eye surgery. 2
Greater awareness of IFIS has led to a progressive decline in related complication rates over successive years. 1

The choice of alpha‑1 blocker should be individualized based on patient age, comorbid conditions, and the specific adverse‑event profile (e.g., risk of ejaculatory dysfunction versus blood‑pressure changes). 1
Tamsulosin 0.4 mg once daily does not require dose titration and provides symptom relief comparable to other agents while producing minimal cardiovascular side effects. 2
Doxazosin and terazosin should be started at low doses and uptitrated gradually to reduce the risk of orthostatic hypotension. 2

Alpha‑1 blocker therapy should not be assumed to provide optimal control of concomitant hypertension in patients with cardiac risk factors; separate antihypertensive management may be necessary. 2
When combined with carvedilol, clinicians should begin with the lowest effective doses, titrate slowly, and monitor blood pressure in both supine and standing positions, especially 2–4 hours after dosing when peak effects occur. 2

Nasal congestion and rhinitis are common side effects of alpha‑1 blockade in the nasal vasculature. 2